Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare and BioInvent broaden antibody collaboration

Bayer HealthCare and BioInvent broaden antibody collaboration

15th October 2013

Bayer HealthCare has signed an extension to a 2008 licence agreement with BioInvent International pertaining to joint antibody research.

The new agreement will see Bayer broadening its access to BioInvent's discovery and development technology platform, facilitating the development of antibodies from BioInvent's n-CoDeR libraries.

These libraries contain more than 20 billion highly diverse, fully human antibody fragments created using BioInvent's patented approach, which generates antibodies with high affinity and selectivity.

BioInvent will receive an undisclosed licence fee to cover new projects plus success-based milestone payments and royalties on products already in development.

Michael Oredsson, chief executive officer of BioInvent, said: "The signing of an extension and broadening of our n-CoDeR technology collaboration with Bayer, we believe, exemplifies the value of our technology and the strength of our collaborations."

This comes after the firm allied with diagnostic company Sysmex Inostics on the creation of companion diagnostics for targeted cancer therapies earlier this month.ADNFCR-8000103-ID-801649401-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.